FDA To Possibly Authorize Pfizer, Merck COVID-19 Antiviral Pills This Week: Bloomberg

The FDA is set to authorize COVID-19 treatment pills from Pfizer Inc PFE and Merck & Co Inc MRK as early as Wednesday, Bloomberg reported, citing people familiar with the matter.

  • The two drugs, especially Pfizer's pill Paxlovid, are seen as promising new oral treatments that can be taken upon onset of symptoms at home to help prevent COVID-19 hospitalizations and deaths.
  • Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
  • Molnupiravir gained a narrow vote in favor of authorization by a panel of advisers to the FDA.
  • Meanwhile, Pfizer's Paxlovid showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.
  • Price Action: MRK shares are up 0.29% at $75.76, PFE stock is down 0.34% at $58.75 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!